{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-07-10T18:41:59.293293+00:00","company":{"ticker":"RVMD","cik":1628171,"company_name":"Revolution Medicines, Inc."},"pagination":{"limit":100,"returned":32,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{"contract_counterparty":[{"display_name":"EQRx, Inc.","detail":"merger","count":1,"first_seen":"2023-08-01T23:59:59+00:00","last_seen":"2023-08-01T23:59:59+00:00","evidence_fact_ids":[125771]},{"display_name":"Genzyme Corporation","detail":"collaboration","count":1,"first_seen":"2022-12-07T23:59:59+00:00","last_seen":"2022-12-07T23:59:59+00:00","evidence_fact_ids":[192645]},{"display_name":"U.S. Bank Trust Company, National Association","detail":"notes_offering","count":1,"first_seen":"2026-04-17T23:59:59+00:00","last_seen":"2026-04-17T23:59:59+00:00","evidence_fact_ids":[24103]}],"lender":[{"display_name":"Royalty Pharma Investments 2019 ICAV","detail":"other","count":1,"first_seen":"2025-06-24T23:59:59+00:00","last_seen":"2025-06-24T23:59:59+00:00","evidence_fact_ids":[45005]},{"display_name":"U.S. Bank Trust Company, National Association","detail":"convertible_notes","count":1,"first_seen":"2026-04-17T23:59:59+00:00","last_seen":"2026-04-17T23:59:59+00:00","evidence_fact_ids":[29844]}],"ma_counterparty":[{"display_name":"EQRx, Inc.","detail":"acquisition","count":2,"first_seen":"2023-11-09T23:59:59+00:00","last_seen":"2023-12-26T23:59:59+00:00","evidence_fact_ids":[85730,95647]}]},"facts":[{"fact_type":"executive_change","fact_key":"77a7f839ee","cik":1628171,"ticker":"RVMD","company_name":"Revolution Medicines, Inc.","filed_at":"2026-06-22T12:00:17+00:00","payload":{"action":"transition","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2026-07-01","interim":true,"role":"senior advisor to the chief executive officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Steve Kelsey changed role as senior advisor to the chief executive officer at Revolution Medicines, Inc..","evidence_excerpt":"Dr. Kelsey will transition from his role as the Company’s president, research and development to a new position as senior advisor to the chief executive officer effective as of July 1, 2026.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001193125-26-276718","anchor_url":"https://secwatch.observer/filing/0001193125-26-276718#claim-77a7f839ee","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1628171/000119312526276718/0001193125-26-276718-index.htm"},{"fact_type":"executive_change","fact_key":"cb5e64ed16","cik":1628171,"ticker":"RVMD","company_name":"Revolution Medicines, Inc.","filed_at":"2026-06-22T12:00:17+00:00","payload":{"action":"retire","action_category":"departure","departure_tone":"retirement","effective_date":"2027-01-04","interim":false,"role":"president, research and development","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Steve Kelsey departed as president, research and development at Revolution Medicines, Inc..","evidence_excerpt":"On June 18, 2026, Steve Kelsey, M.D., FRCP, FRCPath, informed Revolution Medicines, Inc. (the “Company”) of his intent to retire from his employment with the Company effective as of January 4, 2027.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001193125-26-276718","anchor_url":"https://secwatch.observer/filing/0001193125-26-276718#claim-cb5e64ed16","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1628171/000119312526276718/0001193125-26-276718-index.htm"},{"fact_type":"shareholder_vote","fact_key":"e093f298394c96356bf63bfc0f16f919410b49f0","cik":1628171,"ticker":"RVMD","company_name":"Revolution Medicines, Inc.","filed_at":"2026-06-22T12:00:17+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-18","outcome":"passed","proposal_text":"Non-binding advisory approval of named executive officer compensation","proposal_type":"say_on_pay","results":[{"broker_non_votes":"20,813,641","subject":null,"votes_abstain":"176,733","votes_against":"5,554,146","votes_for":"155,110,825","votes_withheld":null}]},"claim":"Revolution Medicines, Inc. shareholders approved Non-binding advisory approval of named executive officer compensation at the 2026-06-18 meeting.","evidence_excerpt":"Votes For Votes Against Abstentions Broker Non-Votes 155,110,825 5,554,146 176,733 20,813,641","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-26-276718","anchor_url":"https://secwatch.observer/filing/0001193125-26-276718#claim-e093f298394c96356bf63bfc0f16f919410b49f0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1628171/000119312526276718/0001193125-26-276718-index.htm"},{"fact_type":"shareholder_vote","fact_key":"680d67fe0d7a7be5c47b161323da191cc11fc110","cik":1628171,"ticker":"RVMD","company_name":"Revolution Medicines, Inc.","filed_at":"2026-06-22T12:00:17+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-18","outcome":"passed","proposal_text":"Ratification of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year ending December 31, 2026","proposal_type":"auditor_ratification","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"139,256","votes_against":"206,306","votes_for":"181,309,783","votes_withheld":null}]},"claim":"Revolution Medicines, Inc. shareholders approved Ratification of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-18 meeting.","evidence_excerpt":"Votes For Votes Against Abstentions 181,309,783 206,306 139,256","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-26-276718","anchor_url":"https://secwatch.observer/filing/0001193125-26-276718#claim-680d67fe0d7a7be5c47b161323da191cc11fc110","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1628171/000119312526276718/0001193125-26-276718-index.htm"},{"fact_type":"shareholder_vote","fact_key":"52951b4bb1aa35804cca93291e4ecc25e79c7e3e","cik":1628171,"ticker":"RVMD","company_name":"Revolution Medicines, Inc.","filed_at":"2026-06-22T12:00:17+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-18","outcome":"passed","proposal_text":"Election of two Class III directors to hold office until the 2029 annual meeting","proposal_type":"director_election","results":[{"broker_non_votes":"20,813,641","subject":"Alexis Borisy","votes_abstain":null,"votes_against":null,"votes_for":"127,181,172","votes_withheld":"33,660,532"},{"broker_non_votes":"20,813,641","subject":"Mark A. Goldsmith, M.D., Ph.D.","votes_abstain":null,"votes_against":null,"votes_for":"157,681,628","votes_withheld":"3,160,076"}]},"claim":"Revolution Medicines, Inc. shareholders approved Election of two Class III directors to hold office until the 2029 annual meeting at the 2026-06-18 meeting.","evidence_excerpt":"Nominee Votes For Votes Withheld Broker Non-Votes Alexis Borisy 127,181,172 33,660,532 20,813,641 Mark A. Goldsmith, M.D., Ph.D. 157,681,628 3,160,076 20,813,641","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-26-276718","anchor_url":"https://secwatch.observer/filing/0001193125-26-276718#claim-52951b4bb1aa35804cca93291e4ecc25e79c7e3e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1628171/000119312526276718/0001193125-26-276718-index.htm"},{"fact_type":"earnings_release","fact_key":"e2457be261da455f7bd5ae3813c5f9d358a407e3","cik":1628171,"ticker":"RVMD","company_name":"Revolution Medicines, Inc.","filed_at":"2026-05-06T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the quarter ended March 31, 2026","report_date":"2026-05-06","result_type":"reported_results","revenue_text":null},"claim":"Revolution Medicines, Inc. reported financial results for the quarter ended March 31, 2026.","evidence_excerpt":"Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its financial results for the quarter ended March 31, 2026, and provided an update on corporate progress.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-208918","anchor_url":"https://secwatch.observer/filing/0001193125-26-208918#claim-e2457be261da455f7bd5ae3813c5f9d358a407e3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1628171/000119312526208918/0001193125-26-208918-index.htm"},{"fact_type":"debt_financing","fact_key":"11bd64c87bcbecbe65d0c10f71bd9277e4b410ee","cik":1628171,"ticker":"RVMD","company_name":"Revolution Medicines, Inc.","filed_at":"2026-04-17T23:59:59+00:00","payload":{"counterparty":"U.S. Bank Trust Company, National Association","effective_date":"2026-04-17","event":"incurrence","instrument_type":"convertible_notes","interest_rate_text":"0.50% per annum","item_codes_triggered":["2.03"],"maturity_text":"May 1, 2033","principal_text":"$500,000,000 aggregate principal amount"},"claim":"Revolution Medicines, Inc. incurred convertible notes of $500,000,000 aggregate principal amount with U.S. Bank Trust Company, National Association at 0.50% per annum maturing May 1, 2033.","evidence_excerpt":"On April 17, 2026, Revolution Medicines, Inc. (the “Company”) issued $500,000,000 aggregate principal amount of its 0.50% Convertible Senior Notes due 2033 (the “Notes”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-161800","anchor_url":"https://secwatch.observer/filing/0001193125-26-161800#claim-11bd64c87bcbecbe65d0c10f71bd9277e4b410ee","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1628171/000119312526161800/0001193125-26-161800-index.htm"},{"fact_type":"material_agreement","fact_key":"b255c3bc98629afe167f7eff72798997fe3de27a","cik":1628171,"ticker":"RVMD","company_name":"Revolution Medicines, Inc.","filed_at":"2026-04-17T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Indenture","agreement_type":"notes_offering","counterparty":"U.S. Bank Trust Company, National Association","effective_date":"2026-04-17","item_codes_triggered":["1.01"],"value_text":"$500,000,000 aggregate principal amount"},"claim":"Revolution Medicines, Inc. entered into Indenture with U.S. Bank Trust Company, National Association valued at $500,000,000 aggregate principal amount (effective 2026-04-17).","evidence_excerpt":"On April 17, 2026, Revolution Medicines, Inc. (the “Company”) issued $500,000,000 aggregate principal amount of its 0.50% Convertible Senior Notes due 2033 (the “Notes”). The Notes were issued pursuant to, and are governed by, an indenture (the “Base Indenture”), dated as of April 17, 2026, between the Company and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”), as supplemented by a First Supplemental Indenture (the “Supplemental Indenture,” and the Base Indenture, as supplemented by the Supplemental Indenture, the “Indenture”), dated as of April 17, 2026, between the Company and the Trustee.","confidence":0.99,"filing_url":"https://secwatch.observer/filing/0001193125-26-161800","anchor_url":"https://secwatch.observer/filing/0001193125-26-161800#claim-b255c3bc98629afe167f7eff72798997fe3de27a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1628171/000119312526161800/0001193125-26-161800-index.htm"},{"fact_type":"debt_financing","fact_key":"01937ca83db609bdbd3ae7915ceacdef815aca31","cik":1628171,"ticker":"RVMD","company_name":"Revolution Medicines, Inc.","filed_at":"2025-06-24T23:59:59+00:00","payload":{"counterparty":"Royalty Pharma Investments 2019 ICAV","effective_date":"2025-06-23","event":"incurrence","instrument_type":"other","interest_rate_text":null,"item_codes_triggered":["2.03"],"maturity_text":"15 years after the first commercial sale of RMC-6236 in the United States","principal_text":"$250.0 million"},"claim":"Revolution Medicines, Inc. incurred debt of $250.0 million with Royalty Pharma Investments 2019 ICAV maturing 15 years after the first commercial sale of RMC-6236 in the United States.","evidence_excerpt":"On June 23, 2025 (the “Effective Date”), Revolution Medicines, Inc. (the “Company”) entered into a revenue participation right purchase and sale agreement (the “Royalty Purchase Agreement”) with Royalty Pharma Investments 2019 ICAV (“Royalty Pharma”). Pursuant to the Royalty Purchase Agreement, in exchange for an upfront payment of $250.0 million, Royalty Pharma purchased from the Company the right to receive tiered revenue payments (the “Royalty Payments”) with respect to worldwide net product sales","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-25-145242","anchor_url":"https://secwatch.observer/filing/0001193125-25-145242#claim-01937ca83db609bdbd3ae7915ceacdef815aca31","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1628171/000119312525145242/0001193125-25-145242-index.htm"},{"fact_type":"executive_change","fact_key":"83ef8076eb","cik":1628171,"ticker":"RVMD","company_name":"Revolution Medicines, Inc.","filed_at":"2025-06-18T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2025-06-26","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Barbara Weber, M.D. resigned as Director at Revolution Medicines, Inc..","evidence_excerpt":"On June 18, 2025, Barbara Weber, M.D., communicated her decision to resign from the board of directors (the “Board”) of Revolution Medicines, Inc.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-25-142735","anchor_url":"https://secwatch.observer/filing/0001193125-25-142735#claim-83ef8076eb","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1628171/000119312525142735/0001193125-25-142735-index.htm"},{"fact_type":"executive_change","fact_key":"60df6ae4ac","cik":1628171,"ticker":"RVMD","company_name":"Revolution Medicines, Inc.","filed_at":"2024-08-07T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-08-05","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Frank K. Clyburn, Jr. was appointed as Director at Revolution Medicines, Inc..","evidence_excerpt":"On August 5, 2024, the board of directors (the “Board”) of the Company increased the authorized size of the Board to ten directors and appointed Frank K. Clyburn, Jr. as a member of the Board.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0000950170-24-092735","anchor_url":"https://secwatch.observer/filing/0000950170-24-092735#claim-60df6ae4ac","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1628171/000095017024092735/0000950170-24-092735-index.htm"},{"fact_type":"earnings_release","fact_key":"0905bef209af73bdd41889ddf8f125f5f2e69924","cik":1628171,"ticker":"RVMD","company_name":"Revolution Medicines, Inc.","filed_at":"2024-05-08T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the quarter ended March 31, 2024","report_date":"2024-05-08","result_type":"reported_results","revenue_text":null},"claim":"Revolution Medicines, Inc. reported financial results for the quarter ended March 31, 2024.","evidence_excerpt":"On May 8, 2024, Revolution Medicines, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2024.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-24-055606","anchor_url":"https://secwatch.observer/filing/0000950170-24-055606#claim-0905bef209af73bdd41889ddf8f125f5f2e69924","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1628171/000095017024055606/0000950170-24-055606-index.htm"},{"fact_type":"earnings_release","fact_key":"07eb062283fcd5a5f4aeb1d49600260f4bc1b8d8","cik":1628171,"ticker":"RVMD","company_name":"Revolution Medicines, Inc.","filed_at":"2024-02-26T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the quarter and year ended December 31, 2023","report_date":"2024-02-26","result_type":"reported_results","revenue_text":null},"claim":"Revolution Medicines, Inc. reported financial results for the quarter and year ended December 31, 2023.","evidence_excerpt":"Revolution Medicines, Inc. (the “Company”) announced its financial results for the quarter and year ended December 31, 2023.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-24-020125","anchor_url":"https://secwatch.observer/filing/0000950170-24-020125#claim-07eb062283fcd5a5f4aeb1d49600260f4bc1b8d8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1628171/000095017024020125/0000950170-24-020125-index.htm"},{"fact_type":"ma_transaction","fact_key":"a538fabc5016628dca86be329878e8fc370e88fe","cik":1628171,"ticker":"RVMD","company_name":"Revolution Medicines, Inc.","filed_at":"2023-12-26T23:59:59+00:00","payload":{"action":"acquisition","closing_date":"2023-11-09","consideration_text":null,"counterparty":"EQRx, Inc.","effective_date":"2023-11-09","item_codes_triggered":["2.01"]},"claim":"Revolution Medicines, Inc. completed an acquisition involving EQRx, Inc. (closed 2023-11-09).","evidence_excerpt":"reporting under Item 2.01 the completion of its previously announced acquisition (the \"Acquisition\") of EQRx, Inc.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-23-302252","anchor_url":"https://secwatch.observer/filing/0001193125-23-302252#claim-a538fabc5016628dca86be329878e8fc370e88fe","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1628171/000119312523302252/0001193125-23-302252-index.htm"},{"fact_type":"shareholder_vote","fact_key":"f36f95b20923369c8ff00f3194756d1f09068f76","cik":1628171,"ticker":"RVMD","company_name":"Revolution Medicines, Inc.","filed_at":"2023-11-09T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-11-08","outcome":"passed","proposal_text":"Approval of the issuance of shares of Revolution Medicines Common Stock (including securities convertible into or exercisable for shares of Revolution Medicines Common Stock) to certain equityholders of EQRx pursuant to Merger Agreement (the \"Share Issuance Proposal\")","proposal_type":"merger_approval","results":[{"broker_non_votes":"0","subject":null,"votes_abstain":"123,934","votes_against":"9,442,157","votes_for":"85,738,003","votes_withheld":"0"}]},"claim":"Revolution Medicines, Inc. shareholders approved Approval of the issuance of shares of Revolution Medicines Common Stock (including securities convertible into or exercisable for shares of Revolution Medicines Common Stock) to certain equityholders of EQRx pursuant to Merger Agreement (the \"Share Issuance Proposal\") at the 2023-11-08 meeting.","evidence_excerpt":"Proposal No. 1: Approval of the issuance of shares of Revolution Medicines Common Stock (including securities convertible into or exercisable for shares of Revolution Medicines Common Stock) to certain equityholders of EQRx pursuant to Merger Agreement (the “Share Issuance Proposal”). The Share Issuance Proposal was approved by the requisite vote of Revolution Medicines’ stockholders. Votes For Votes Against Abstentions Broker Non-Votes 85,738,003 9,442,157 123,934 —","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001193125-23-274137","anchor_url":"https://secwatch.observer/filing/0001193125-23-274137#claim-f36f95b20923369c8ff00f3194756d1f09068f76","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1628171/000119312523274137/0001193125-23-274137-index.htm"},{"fact_type":"ma_transaction","fact_key":"d891766885c841ef437f454f1a62f81c6c95d022","cik":1628171,"ticker":"RVMD","company_name":"Revolution Medicines, Inc.","filed_at":"2023-11-09T23:59:59+00:00","payload":{"action":"acquisition","closing_date":"2023-11-09","consideration_text":null,"counterparty":"EQRx, Inc.","effective_date":"2023-11-09","item_codes_triggered":["2.01"]},"claim":"Revolution Medicines, Inc. completed an acquisition involving EQRx, Inc. (closed 2023-11-09).","evidence_excerpt":"On November 9, 2023, Revolution Medicines, Inc., a Delaware corporation (“Revolution Medicines”), completed the previously announced acquisition of EQRx, Inc., a Delaware corporation (“EQRx”)","confidence":0.98,"filing_url":"https://secwatch.observer/filing/0001193125-23-274137","anchor_url":"https://secwatch.observer/filing/0001193125-23-274137#claim-d891766885c841ef437f454f1a62f81c6c95d022","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1628171/000119312523274137/0001193125-23-274137-index.htm"},{"fact_type":"executive_change","fact_key":"d07c06681b","cik":1628171,"ticker":"RVMD","company_name":"Revolution Medicines, Inc.","filed_at":"2023-11-09T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-11-09","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Sandra J. Horning was appointed as Director at Revolution Medicines, Inc..","evidence_excerpt":"the Revolution Medicines board of directors (the “Board”) appointed Sandra J. Horning, M.D., as a member of the Board.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001193125-23-274137","anchor_url":"https://secwatch.observer/filing/0001193125-23-274137#claim-d07c06681b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1628171/000119312523274137/0001193125-23-274137-index.htm"},{"fact_type":"earnings_release","fact_key":"0c1614c67ffbc3b005ee29f6ebbca15ce8ad037e","cik":1628171,"ticker":"RVMD","company_name":"Revolution Medicines, Inc.","filed_at":"2023-11-06T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the quarter ended September 30, 2023","report_date":"2023-11-06","result_type":"reported_results","revenue_text":null},"claim":"Revolution Medicines, Inc. reported financial results for the quarter ended September 30, 2023.","evidence_excerpt":"On November 6, 2023, Revolution Medicines, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2023.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-23-059374","anchor_url":"https://secwatch.observer/filing/0000950170-23-059374#claim-0c1614c67ffbc3b005ee29f6ebbca15ce8ad037e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1628171/000095017023059374/0000950170-23-059374-index.htm"},{"fact_type":"executive_change","fact_key":"330d4054a2","cik":1628171,"ticker":"RVMD","company_name":"Revolution Medicines, Inc.","filed_at":"2023-09-05T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2023-09-05","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Eric T. Schmidt resigned as Director at Revolution Medicines, Inc..","evidence_excerpt":"On August 31, 2023, Eric T. Schmidt, Ph.D., resigned from the Board of Directors (the “Board”) of Revolution Medicines, Inc. (the “Company”), effective September 5, 2023.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-23-228515","anchor_url":"https://secwatch.observer/filing/0001193125-23-228515#claim-330d4054a2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1628171/000119312523228515/0001193125-23-228515-index.htm"},{"fact_type":"earnings_release","fact_key":"b518f88762e33689b03a7ba6fb2ffea0bce974d0","cik":1628171,"ticker":"RVMD","company_name":"Revolution Medicines, Inc.","filed_at":"2023-08-08T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the quarter ended June 30, 2023","report_date":"2023-08-08","result_type":"reported_results","revenue_text":null},"claim":"Revolution Medicines, Inc. reported financial results for the quarter ended June 30, 2023.","evidence_excerpt":"On August 8, 2023, Revolution Medicines, Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2023.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-23-039773","anchor_url":"https://secwatch.observer/filing/0000950170-23-039773#claim-b518f88762e33689b03a7ba6fb2ffea0bce974d0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1628171/000095017023039773/0000950170-23-039773-index.htm"},{"fact_type":"material_agreement","fact_key":"095a86ae96aaed41daa68a27c1933559f190ab22","cik":1628171,"ticker":"RVMD","company_name":"Revolution Medicines, Inc.","filed_at":"2023-08-01T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Agreement and Plan of Merger","agreement_type":"merger","counterparty":"EQRx, Inc.","effective_date":"2023-07-31","item_codes_triggered":["1.01"],"value_text":null},"claim":"Revolution Medicines, Inc. entered into Agreement and Plan of Merger with EQRx, Inc. (effective 2023-07-31).","evidence_excerpt":"On July 31, 2023, Revolution Medicines, Inc., a Delaware corporation (the “Company”), EQRx, Inc., a Delaware corporation (“EQRx”), Equinox Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of the Company (“Merger Sub I”), and Equinox Merger Sub II LLC, a Delaware limited liability company and a direct, wholly owned subsidiary of the Company (“Merger Sub II”), entered into an Agreement and Plan of Merger (the “Merger Agreement”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-23-199907","anchor_url":"https://secwatch.observer/filing/0001193125-23-199907#claim-095a86ae96aaed41daa68a27c1933559f190ab22","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1628171/000119312523199907/0001193125-23-199907-index.htm"},{"fact_type":"shareholder_vote","fact_key":"c6b15c6ab2d28cf56f1d0815af02a519e4137561","cik":1628171,"ticker":"RVMD","company_name":"Revolution Medicines, Inc.","filed_at":"2023-06-09T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-06-08","outcome":"passed","proposal_text":"Non-binding advisory approval of the compensation of the Company’s named executive officers as disclosed in the Proxy Statement.","proposal_type":"say_on_pay","results":[{"broker_non_votes":"5,346,837","subject":null,"votes_abstain":"7,232","votes_against":"773,142","votes_for":"88,731,273","votes_withheld":null}]},"claim":"Revolution Medicines, Inc. shareholders approved Non-binding advisory approval of the compensation of the Company’s named executive officers as disclosed in the Proxy Statement. at the 2023-06-08 meeting.","evidence_excerpt":"Proposal 3 . The Company’s stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement, pursuant to the compensation disclosure rules of the SEC. The results of the vote were as follows: Votes For Votes Against Abstentions Broker Non-Votes 88,731,273 773,142 7,232 5,346,837","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-23-164446","anchor_url":"https://secwatch.observer/filing/0001193125-23-164446#claim-c6b15c6ab2d28cf56f1d0815af02a519e4137561","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1628171/000119312523164446/0001193125-23-164446-index.htm"},{"fact_type":"shareholder_vote","fact_key":"878e9aa3fc129f2a91cf1ca3d9744d421d6b819e","cik":1628171,"ticker":"RVMD","company_name":"Revolution Medicines, Inc.","filed_at":"2023-06-09T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-06-08","outcome":"passed","proposal_text":"Ratification of the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023.","proposal_type":"auditor_ratification","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"1,147","votes_against":"6,594","votes_for":"94,850,743","votes_withheld":null}]},"claim":"Revolution Medicines, Inc. shareholders approved Ratification of the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023. at the 2023-06-08 meeting.","evidence_excerpt":"Proposal 2 . The Company’s stockholders ratified the appointment, by the audit committee of the Company’s board of directors, of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2023. The results of the vote were as follows: Votes For Votes Against Abstentions 94,850,743 6,594 1,147","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-23-164446","anchor_url":"https://secwatch.observer/filing/0001193125-23-164446#claim-878e9aa3fc129f2a91cf1ca3d9744d421d6b819e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1628171/000119312523164446/0001193125-23-164446-index.htm"},{"fact_type":"shareholder_vote","fact_key":"0434eb08474686e0a52ed8bd8a763eb187f9bc36","cik":1628171,"ticker":"RVMD","company_name":"Revolution Medicines, Inc.","filed_at":"2023-06-09T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-06-08","outcome":"passed","proposal_text":"Election of three Class III directors to hold office until the 2026 annual meeting of stockholders or until their respective successors are elected and qualified.","proposal_type":"director_election","results":[{"broker_non_votes":"5,346,837","subject":"Alexis Borisy","votes_abstain":null,"votes_against":null,"votes_for":"41,488,497","votes_withheld":"48,023,150"},{"broker_non_votes":"5,346,837","subject":"Mark A. Goldsmith, M.D., Ph.D.","votes_abstain":null,"votes_against":null,"votes_for":"87,159,600","votes_withheld":"2,352,047"},{"broker_non_votes":"5,346,837","subject":"Barbara Weber, M.D.","votes_abstain":null,"votes_against":null,"votes_for":"73,933,569","votes_withheld":"15,578,078"}]},"claim":"Revolution Medicines, Inc. shareholders approved Election of three Class III directors to hold office until the 2026 annual meeting of stockholders or until their respective successors are elected and qualified. at the 2023-06-08 meeting.","evidence_excerpt":"Proposal 1 . The Company’s stockholders elected three Class III directors to hold office until the 2026 annual meeting of stockholders or until their respective successors are elected and qualified. The results of the vote were as follows: Nominee Votes For Votes Withheld Broker Non-Votes Alexis Borisy 41,488,497 48,023,150 5,346,837 Mark A. Goldsmith, M.D., Ph.D. 87,159,600 2,352,047 5,346,837 Barbara Weber, M.D. 73,933,569 15,578,078 5,346,837","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-23-164446","anchor_url":"https://secwatch.observer/filing/0001193125-23-164446#claim-0434eb08474686e0a52ed8bd8a763eb187f9bc36","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1628171/000119312523164446/0001193125-23-164446-index.htm"},{"fact_type":"earnings_release","fact_key":"ace8c1b4c920fabd282e13e81681a7c0f7544126","cik":1628171,"ticker":"RVMD","company_name":"Revolution Medicines, Inc.","filed_at":"2023-05-08T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the quarter ended March 31, 2023","report_date":"2023-05-08","result_type":"reported_results","revenue_text":null},"claim":"Revolution Medicines, Inc. reported financial results for the quarter ended March 31, 2023.","evidence_excerpt":"On May 8, 2023, Revolution Medicines, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2023.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-23-018785","anchor_url":"https://secwatch.observer/filing/0000950170-23-018785#claim-ace8c1b4c920fabd282e13e81681a7c0f7544126","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1628171/000095017023018785/0000950170-23-018785-index.htm"},{"fact_type":"earnings_release","fact_key":"7ee8307a835e196a1f30fc6ad849497f383d3d57","cik":1628171,"ticker":"RVMD","company_name":"Revolution Medicines, Inc.","filed_at":"2023-02-27T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the quarter and year ended December 31, 2022","report_date":"2023-02-27","result_type":"reported_results","revenue_text":null},"claim":"Revolution Medicines, Inc. reported financial results for the quarter and year ended December 31, 2022.","evidence_excerpt":"On February 27, 2023, Revolution Medicines, Inc. (the “Company”) announced its financial results for the quarter and year ended December 31, 2022.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-23-004638","anchor_url":"https://secwatch.observer/filing/0000950170-23-004638#claim-7ee8307a835e196a1f30fc6ad849497f383d3d57","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1628171/000095017023004638/0000950170-23-004638-index.htm"},{"fact_type":"earnings_release","fact_key":"b3a101814745ebb411525adf2d37f58d47322f42","cik":1628171,"ticker":"RVMD","company_name":"Revolution Medicines, Inc.","filed_at":"2023-01-10T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":"between $245 million and $265 million","period_text":"the year ended December 31, 2022","report_date":"2023-01-10","result_type":"guidance_update","revenue_text":null},"claim":"Revolution Medicines, Inc. reported the year ended December 31, 2022 results: net income between $245 million and $265 million. Guidance reaffirmed.","evidence_excerpt":"On January 10, 2023, Revolution Medicines, Inc. (the “Company”) confirmed to investors that it continues to expect that its net loss for the year ended December 31, 2022 to be between $245 million and $265 million, which includes estimated non-cash stock-based compensation expense of approximately $30 million to $35 million.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-23-000597","anchor_url":"https://secwatch.observer/filing/0000950170-23-000597#claim-b3a101814745ebb411525adf2d37f58d47322f42","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1628171/000095017023000597/0000950170-23-000597-index.htm"},{"fact_type":"material_agreement","fact_key":"b2c6a29d9f3628a5d0879156c646743d53644e51","cik":1628171,"ticker":"RVMD","company_name":"Revolution Medicines, Inc.","filed_at":"2022-12-07T23:59:59+00:00","payload":{"action":"termination","agreement_name":"Sanofi Agreement","agreement_type":"collaboration","counterparty":"Genzyme Corporation","effective_date":"2023-06-04","item_codes_triggered":["1.02"],"value_text":null},"claim":"Revolution Medicines, Inc. terminated Sanofi Agreement with Genzyme Corporation (effective 2023-06-04).","evidence_excerpt":"On December 6, 2022, Revolution Medicines, Inc. (the “Company”) received notice of Genzyme Corporation’s decision to terminate for convenience that certain Collaborative Research, Development and Commercialization Agreement by and between the Company and Aventis, Inc., dated June 8, 2018, as assigned by Aventis, Inc. to Genzyme Corporation (as amended, the “Sanofi Agreement”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-22-300162","anchor_url":"https://secwatch.observer/filing/0001193125-22-300162#claim-b2c6a29d9f3628a5d0879156c646743d53644e51","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1628171/000119312522300162/0001193125-22-300162-index.htm"},{"fact_type":"earnings_release","fact_key":"fc51d8536b23121da4a3ea9dfb0363aa94653ed5","cik":1628171,"ticker":"RVMD","company_name":"Revolution Medicines, Inc.","filed_at":"2022-11-07T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"quarter ended September 30, 2022","report_date":"2022-11-07","result_type":"reported_results","revenue_text":null},"claim":"Revolution Medicines, Inc. reported financial results for quarter ended September 30, 2022.","evidence_excerpt":"On November 7, 2022, Revolution Medicines, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2022.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-22-279068","anchor_url":"https://secwatch.observer/filing/0001193125-22-279068#claim-fc51d8536b23121da4a3ea9dfb0363aa94653ed5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1628171/000119312522279068/0001193125-22-279068-index.htm"},{"fact_type":"executive_change","fact_key":"761abcd289","cik":1628171,"ticker":"RVMD","company_name":"Revolution Medicines, Inc.","filed_at":"2022-09-01T23:59:59+00:00","payload":{"action":"promoted","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2022-09-01","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Jack Anders changed role as Chief Financial Officer at Revolution Medicines, Inc..","evidence_excerpt":"On September 1, 2022, the Board of Directors (the “Board”) of Revolution Medicines, Inc. (the “Company”) promoted Jack Anders, age 45, to serve as the Chief Financial Officer of the Company, effective immediately.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-22-236516","anchor_url":"https://secwatch.observer/filing/0001193125-22-236516#claim-761abcd289","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1628171/000119312522236516/0001193125-22-236516-index.htm"},{"fact_type":"executive_change","fact_key":"8448270bf5","cik":1628171,"ticker":"RVMD","company_name":"Revolution Medicines, Inc.","filed_at":"2022-07-13T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"not_disclosed","effective_date":"2022-07-12","interim":false,"role":"Director","role_category":"director","successor_name":"Lorence Kim","successor_named":true},"claim":"Neil Exter resigned as Director at Revolution Medicines, Inc..","evidence_excerpt":"Dr. Kim was appointed to fill the vacancy on the Board created by the resignation of Neil Exter, who resigned from the Board, effective July 12, 2022.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-22-192292","anchor_url":"https://secwatch.observer/filing/0001193125-22-192292#claim-8448270bf5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1628171/000119312522192292/0001193125-22-192292-index.htm"},{"fact_type":"executive_change","fact_key":"ce31c7181c","cik":1628171,"ticker":"RVMD","company_name":"Revolution Medicines, Inc.","filed_at":"2022-07-13T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-07-12","interim":false,"role":"Class I Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Lorence Kim was appointed as Class I Director at Revolution Medicines, Inc..","evidence_excerpt":"On July 9, 2022, the Board of Directors (“Board”) of Revolution Medicines, Inc. (the “Company”) appointed Lorence Kim, M.D., as a member of the Board, effective July 12, 2022.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-22-192292","anchor_url":"https://secwatch.observer/filing/0001193125-22-192292#claim-ce31c7181c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1628171/000119312522192292/0001193125-22-192292-index.htm"}]}